U.S. Markets open in 4 hrs 14 mins

Mesoblast Limited (MSB.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
1.6350-0.0150 (-0.91%)
At close: 4:10PM AEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6500
Open1.6500
Bid1.6350 x 0
Ask1.6450 x 0
Day's Range1.6150 - 1.6600
52 Week Range1.5700 - 5.7000
Volume1,273,951
Avg. Volume3,078,483
Market Cap1.058B
Beta (5Y Monthly)2.58
PE Ratio (TTM)N/A
EPS (TTM)-0.2520
Earnings DateNov 18, 2021 - Nov 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Operational Highlights and Financial Results for the Year Ended June 30, 2021

    NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the fourth quarter and full-year ended June 30, 2021 (FY2021). “During this calendar year we made significant progress in both regulatory and clinical outcomes for our lead product candidate, remestemcel-L, after experiencing a disappointing set-back last year” said Silviu It

  • GlobeNewswire

    Mesoblast Corporate Update and Financial Results Webcast

    NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended June 30, 2021. The webcast will begin at 7.00pm EDT, Monday, August 30; 9.00am AEST, Tuesday, August 31, 2021. It can be accessed via: https://webcast.boardroom.media/mesoblast-limited/20210826/NaN61036c41df5665001c97fc67

  • Simply Wall St.

    Loss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-Term

    With the business potentially at an important milestone, we thought we'd take a closer look at Mesoblast Limited's...